Home › Funds › GREAT POINT PARTNERS LLC › SLN
GREAT POINT PARTNERS LLC position in SLN
SILENCE THERAPEUTICS PLC · Health Care
GREAT POINT PARTNERS LLC reported holding 450,000 shares of SLN (SILENCE THERAPEUTICS PLC) in its Q2 2026 13F filing — a position valued at US$4.9M, representing 1.04% of its reported portfolio and ranking #31 among its reported holdings. GREAT POINT PARTNERS LLC has disclosed SLN holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How GREAT POINT PARTNERS LLC's SLN position evolved
GREAT POINT PARTNERS LLC first disclosed a stake in SLN in Q4 2025 at 808,032 shares (US$4.9M). The position peaked in Q1 2026 at 1,020,489 shares, worth US$5.4M. Across 3 filings, GREAT POINT PARTNERS LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 450,000 shares valued at US$4.9M — a reduction of -570,489 shares quarter over quarter.. Notable position changes include a 26% increase in Q1 2026 (shares rose 108% over the following quarter), a 56% trim in Q2 2026 (shares were roughly flat over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 808.03K | $4.91M | New |
| Q1 2026 | 1.02M | $5.38M | Add |
| Q2 2026 | 450.00K | $4.94M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SLN and 13F data
SLN (SILENCE THERAPEUTICS PLC) is a Health Care company. 35 other funds we track also report a position in SLN — the largest reported positions include Siren, L.L.C. (US$36.4M), TCG Crossover Management, LLC (US$33.3M), Redmile Group, LLC (US$23.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SLN
- Siren, L.L.C. 3.31M sh · $36.36M · Q2 2026
- TCG Crossover Management, LLC 3.03M sh · $33.31M · Q2 2026
- Redmile Group, LLC 2.16M sh · $23.77M · Q2 2026
- Nantahala Capital Management, LLC 1.35M sh · $14.79M · Q2 2026
- Nextech Invest Ltd. 952.40K sh · $10.46M · Q2 2026
- 5AM Venture Management, LLC 476.20K sh · $5.23M · Q2 2026
- Tetragon Partners GP Ltd 300.00K sh · $3.29M · Q2 2026
- Ishara Investments LP 55.35K sh · $2.43M · Q2 2026
- Propel Bio Management, LLC 191.73K sh · $2.11M · Q2 2026
- M28 Capital Management LP 101.20K sh · $1.11M · Q2 2026
More on GREAT POINT PARTNERS LLC
FAQ
How long has GREAT POINT PARTNERS LLC held SLN?
GREAT POINT PARTNERS LLC has disclosed SLN holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is GREAT POINT PARTNERS LLC's current position in SLN?
As of Q2 2026, GREAT POINT PARTNERS LLC holds 450.00K shares of SLN (SILENCE THERAPEUTICS PLC), valued at $4.94M, representing 1.04% of its reported portfolio and ranking #31.
Has GREAT POINT PARTNERS LLC been buying or selling SLN?
In the latest 13F filing (Q2 2026), GREAT POINT PARTNERS LLC reduced its position in SLN. The position peaked in Q1 2026 at 1.02M shares.
Which other funds hold SLN?
Other major institutional holders of SLN include Siren, L.L.C., TCG Crossover Management, LLC, Redmile Group, LLC, among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.